PRECLINICAL INVESTIGATION OF ALKYLATING AGENTS IN CANCER CHEMOTHERAPY
- 1 October 1969
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 163 (2) , 954-994
- https://doi.org/10.1111/j.1749-6632.1969.tb24914.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- 1,6-Dibromo-1,6-dideoxy-dulcitol: a New Antitumoral AgentNature, 1967
- The Synthesis of Potential Anticancer Agents. XXXVI. N-Nitrosoureas.1 II. Haloalkyl DerivativesJournal of Medicinal Chemistry, 1966
- Complete Inhibition of Mouse Leukaemia L1210 by 5(or 4)-[3,3-Mbis (2-Chloroethyl)-l-triazeno]imidazole-4(or 5)-carboxamide (NSC-82196)Nature, 1966
- New treatment schedule with improved survival in childhood leukemia. Intermittent parenteral vs daily oral administration of methotrexate for maintenance of induced remission. Acute leukemia group BPublished by American Medical Association (AMA) ,1965
- Progress and Perspectives in the Chemotherapy of Acute LeukemiaPublished by Elsevier ,1965
- Drug Synergism in Antineoplastic ChemotherapyPublished by Elsevier ,1964
- Quantitative Concepts in the Clinical Study of DrugsPublished by Elsevier ,1964
- ‘Dual Antagonists’; Alkyl N-(bis-(ethylenimido)phosphoro)-carbamates; a New Series of Anti-Tumour AgentsNature, 1959
- BUSULFAN (1,4‐DIMETHANESULFONYLOXYBUTANE, MYLERAN): SUMMARY OF CLINICAL, RESULTSAnnals of the New York Academy of Sciences, 1958